ArticleFrontiers in public health2025
Long-term mortality and hospitalisation among Italian veterans deployed to the Balkans: a retrospective longitudinal study based on individual linkage with national health data.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The potential health risks among veterans deployed to the Balkans have long been debated internationally. In Italy concern about cancer risk in veterans deployed to the Balkans in 1995-2004 (SEBAL cohort) originated from an initial study reporting an excess risk of Hodgkin's lymphoma. Subsequent studies have not fully dispelled these concerns due to methodological shortcomings and the lack of a national cancer registry. Our aim is to investigate long-term mortality and hospitalisation risk in SEBAL veterans for cancer and other major pathologies in comparison to the general population and to non-deployed military peers. Methods: By linking with national archives of causes of death (1999-2018) and hospital discharges (2005-2018), long-term mortality (20 years) and hospitalisation (14 years) of the SEBAL cohort (71,144 soldiers) were evaluated, for the first time, for major disease groups and 27 cancer types. Standardized Mortality Ratios (SMR) and Standardized Hospitalisation Ratios (SHR) were used to compare health outcomes versus the Italian population (IP) and a military cohort never deployed abroad (114,260 Carabinieri). Results: The SEBAL cohort showed a lower risk of death and hospitalisation than both control populations for all natural causes (SMR = 0.40 and SHR = 0.80 vs. IP; SMR = 0.72 and SHR = 0.80 vs. Carabinieri), infectious, endocrine, respiratory, circulatory, digestive and genitourinary diseases, with the only exception of a significantly higher hospitalisation risk for musculoskeletal diseases vs. IP (SHR = 1.27). Reduced risks of hospitalisation and death were found for all cancers (SHR = 0.82 and SMR = 0.56 vs. IP; SHR = 0.91 and SMR = 0.78 vs. Carabinieri), head and neck, respiratory and digestive cancers. Marginally increased hospitalisation risks vs. IP, with no effect on mortality, were observed for thyroid cancer (+39%) and skin melanoma (+32%). For all other solid cancers, hospitalisation and death risks were lower or not significantly different. We found no increased risk for hematological neoplasms, including Hodgkin's lymphoma. Conclusion: Overall, the results of this observational study of unprecedented follow-up and completeness do not support specific long-term risks of mortality or hospitalisation linked to peacekeeping missions to the Balkans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.